Janus Henderson Group PLC Boosts Position in Ascendis Pharma A/S (NASDAQ:ASND)

Janus Henderson Group PLC grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,186,694 shares of the biotechnology company’s stock after buying an additional 267,881 shares during the period. Janus Henderson Group PLC owned 6.90% of Ascendis Pharma A/S worth $625,075,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ASND. Erste Asset Management GmbH purchased a new stake in Ascendis Pharma A/S in the third quarter worth $2,936,000. Acuta Capital Partners LLC purchased a new stake in Ascendis Pharma A/S in the third quarter worth $3,136,000. Finepoint Capital LP grew its stake in Ascendis Pharma A/S by 0.4% in the third quarter. Finepoint Capital LP now owns 190,072 shares of the biotechnology company’s stock worth $28,380,000 after purchasing an additional 800 shares during the period. The Manufacturers Life Insurance Company grew its stake in Ascendis Pharma A/S by 49.5% in the third quarter. The Manufacturers Life Insurance Company now owns 71,307 shares of the biotechnology company’s stock worth $10,647,000 after purchasing an additional 23,595 shares during the period. Finally, Loomis Sayles & Co. L P grew its stake in Ascendis Pharma A/S by 35.3% in the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after purchasing an additional 48,120 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $133.51 on Tuesday. Ascendis Pharma A/S has a 52 week low of $101.43 and a 52 week high of $161.00. The business has a 50-day simple moving average of $131.91 and a two-hundred day simple moving average of $132.38.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Analysts forecast that Ascendis Pharma A/S will post -7.45 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ASND shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. JPMorgan Chase & Co. cut their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Wedbush reissued an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.